Name: UTHR: United Therapeutics Corp Latest Stock Price, Analysis, News and Trading Ideas
Creator: Stocktwits

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Investors are fueling speculation around SpaceX as interest intensifies regarding the broader space economy and potential competitive positioning against other major tech players.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is seeing volatile trading as investors digest strong quarterly results and raised guidance, while some community members weigh the stock's significant recent gains against high valuation expectations. The conversation is currently split between those frustrated by the post-earnings pullback and bullish long-term investors pointing to the company's accelerating data center growth and AI infrastructure potential.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

Investors are closely monitoring SLV as silver retests historic support levels following significant volatility linked to shifting Middle East geopolitical tensions and persistent inflation. While the community debates whether the metal has found a definitive bottom, market participants are split between those accumulating physical silver as a long-term hedge against fiat debasement and those wary of the industrial demand cooling or further short-term downside.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is rallying after management clarified supply chain guidance at a recent investor conference, helping to dispel post-earnings skepticism and renewing focus on record operating cash flows. The community is actively discussing the stock's potential for a breakout to new highs as hyperscaler demand for AI networking infrastructure continues to drive strong growth.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is currently in the spotlight as investors anticipate the company's next earnings report, with community sentiment heavily focused on its track record of beating estimates and potential for a significant re-rating. Much of the discourse centers on the stock's recent volatility and a new $1 billion credit facility, which has sparked speculation about future M&A activity and long-term scaling opportunities.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is seeing heavy community discussion and bullish sentiment following strong Q2 revenue growth that exceeded expectations and a guidance raise. Investors are closely monitoring the company's ability to scale manufacturing and secure new contracts as a potential catalyst to squeeze short positions and drive the stock toward prior highs.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is under heavy selling pressure as investors react to a failed phase 3 trial for ziltivekimab, raising broader concerns about the company's ability to innovate beyond its core GLP-1 business. While the company maintains its long-term financial guidance, the community is actively debating whether this decline represents a buying opportunity for a global market leader or a sign of deeper pipeline stagnation compared to competitors.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co

Walt Disney Co. is trending as investors weigh the stock's long-term valuation against its recent price consolidation and upcoming fiscal third-quarter earnings report. Community discussion is polarized, with some traders anticipating a bullish breakout driven by strong box office performance and streaming growth, while others express frustration over the stock's sluggish historical performance and ongoing debates regarding corporate strategy and leadership.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is experiencing heightened investor interest driven by strong Phase 3 clinical data, institutional accumulation, and ongoing speculation regarding potential strategic partnerships or a buyout. Community sentiment is largely bullish, with active discussions focused on the company's progress toward a BLA filing and its potential to address significant unmet needs in oncology.

Cameco Corp. engages in the provision of uranium. It operates through the Uranium and Fuel Services segments. The Uranium segment is involved in the exploration for, mining, milling, purchase, and sale of uranium concentrate. The Fuel Services segment deals with the refining, conversion, and fabrication of uranium concentrate and the purchase and sale of conversion services. The company was founded in 1988 and is headquartered in Saskatoon, Canada.

Cameco Corp.

Cameco Corp is trending as investors weigh potential production disruptions in its Canadian mines alongside increased nuclear demand from the AI data center boom. The community remains divided between long-term investors holding for a multi-year uranium supply cycle and traders reacting to heightened volatility fueled by energy sector geopolitics.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

UTHR or SDZNY: Which Is the Better Value Stock Right Now?

UTHR vs. SDZNY: Which Stock Is the Better Value Option?

Should You Invest in Liquidia Corporation Stock Ahead of Q2 Earnings? 

LQDA heads into its Q2 earnings with Yutrepia driving growth, rising profitability and a self-funded pipeline as investors watch quarterly performance.

Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth

Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that The Lancet has published full results of its ADVANCE OUTCOMES study, available here. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Ralinepag...

Liquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?

Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.

United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the companys Board of Directors appointed Victor Dzau, M.D., to its Board on July 22, 2026.This press release features multimedia. View the full release here...

United Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 Release

United Therapeutics (UTHR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can LQDA's Differentiated PAH Strategy Drive Long-Term Growth?

Liquidia's Yutrepia is driving strong growth with rapid commercial adoption as the company expands its pipeline and competes in the evolving PAH market.

United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release that will be issued on Wednesday, August 5, 2026, at approximately 6:30 a.m. Eastern Time.United Therapeutics will host a public webcast on Wednesday...

Can LQDA's Yutrepia Drive Growth in the Competitive PAH Market?

LQDA's Yutrepia posts a strong commercial debut, but sustaining growth will hinge on standing out in the crowded PAH market as competition intensifies.

$UTHR Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $6.32 down -11.98% YoY
• Reported revenue of $781.5M down -1.62% YoY

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

United Therapeutics Corp

UTHR Holds As Tyvaso Shows 33% Lower Worsening Risk In Rare Lung Scarring Disease

Equity

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

UTHRUnited Therapeutics Corp

Fundamentals

Connect Stocktwits to ChatGPT

Latest UTHR News